Extension to Study MALARIA-055 PRI (NCT00866619) for Evaluation of Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine (SB257049) in Infants and Children in Africa
Phase of Trial: Phase III
Latest Information Update: 30 Jun 2017
At a glance
- Drugs GSK 257049 (Primary)
- Indications Falciparum malaria
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 15 Feb 2017 Status changed from recruiting to completed.
- 21 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 08 Aug 2014 New trial record